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Abstract
GTP cyclohydrolase I catalyzes the first step in folic acid biosynthesis in bacteria and plants, 
biopterin biosynthesis in mammals, and the biosynthesis of 7-deazaguanosine modified tRNA 
nucleosides in bacteria and archaea. The type IB GTP cyclohydrolase (GCYH-IB) is a 
prokaryotic-specific enzyme found in a number of pathogens. GCYH-IB is structurally distinct 
from the canonical type IA GTP cyclohydrolase involved in biopterin biosynthesis in humans and 
animals, and thus is of interest as a potential antibacterial drug target. We report kinetic and 
inhibition data of Neisseria gonorrhoeae GCYH-IB, and two high-resolution crystal structures of 
the enzyme; one in complex with the reaction intermediate analog and competitive inhibitor 8-
oxo-GTP, and one with a TRIS molecule bound in the active site and mimicking another reaction 
intermediate. Comparison with the type IA enzyme bound to 8-oxo-GTP reveals an inverted mode 
of binding of the inhibitor ribosyl moiety and, together with site-directed mutagenesis data, shows 
that the two enzymes utilize different strategies for catalysis. Notably, the inhibitor interacts with a 
conserved active site Cys149, and this residue is S-nitrosylated in the structures. This is the first 
structural characterization of a biologically S-nitrosylated bacterial protein. Mutagenesis and 
biochemical analyses demonstrate that Cys149 is essential for the cyclohydrolase reaction, and S-
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nitrosylation maintains enzyme activity, suggesting a potential role of the S-nitrosothiol in 
catalysis.
Keywords
Transfer RNA (tRNA); bacterial metabolism; metalloenzyme; 7-deazaguanosine; modified 
nucleoside; Post-Translational Modification (PTM)
Introduction
GTP cyclohydrolase-I (GCYH-I; FolE) is a Zn2+-dependent enzyme that catalyzes the 
conversion of GTP to 7,8-dihydroneopterin triphosphate (H2NTP), the first intermediate in 
the de novo tetrahydrofolate (THF, folate) biosynthesis pathway in bacteria, fungi and plants 
(Fig. 1) [1]. THF is an essential cofactor involved in one carbon transfer reactions in the 
biosynthesis of purines, thymidylate, panthothenate, glycine, serine and methionine in all 
domains of life [1], and formylmethionyl-tRNA in bacteria [2]. GCYH-I also catalyzes the 
first step in the biosynthesis of the 7-deazaguanosine modified tRNA nucleosides queuosine 
and archaeosine in bacteria and archaea [3], the 7-deazapurine natural products in some 
bacteria [4], and the 7-deazaguanosine modified nucleosides recently discovered in the 
genomes of some organisms [5]. GCYH-I is also found in mammals and other higher 
eukaryotes where it catalyzes the first and rate-limiting step of the tetrahydrobiopterin (BH4) 
pathway (Fig. 1) which functions in mammals as a cofactor of aromatic amino acid 
hydroxylases, nitric oxide synthase, and glyceryl ether monooxygenase [6].
GCYH-I has been studied in some detail both biochemically and structurally. It is part of the 
tunneling-fold (T-fold) structural superfamily, a small but catalytically diverse group of 
pterin/purine binding proteins that utilize a common oligomerization of the T-fold domain, 
the core structural component of the superfamily. The T-fold domain is comprised of a 4-
stranded antiparallel β-sheet and two helices, that upon assembly form a β2nαn barrel [7]. 
The functional enzymes are comprised of two barrels that join in a head-to-head fashion, 
forming a tunnel-like center (the origin of the name).
The GCYH-I catalyzed conversion of GTP to H2NTP is a mechanistically complex 
transformation that involves hydrolytic opening of the purine ring at C-8 of GTP to generate 
an N-formyl intermediate, followed by deformylation and subsequent rearrangement and 
cyclization of the ribosyl moiety to generate the pterin system. This mechanistic complexity 
coupled with the biological importance of GCYH-I has made the enzyme the subject of 
interest since its discovery by Burg and Brown 48 years ago [8]. While the outlines for the 
chemical mechanism of the reaction were proposed shortly after the enzyme discovery [9], 
only relatively recently has an understanding of the molecular basis for GCYH-I catalysis 
begun to emerge.
Despite the essential role of GCYH-I as the initiating step in the bacterial folate pathway, its 
role in the biopterin pathway in humans, coupled with the high homology between the E. 
coli and human GCYH-I enzymes, precluded GCYH-I as a viable target for new 
antibacterials. However, a significant number of bacteria possess a second class of GCYH-I 
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enzymes (COG1469) that display virtually no sequence homology to the canonical GCYH-I 
despite exhibiting the high topological homology characteristic of this superfamily. The new 
subfamily of GCYH-I is prokaryotic specific and was named GCYH-IB, while the canonical 
enzymes were renamed GCYH-IA [10]. Notably, GCYH-IB is found in a number of 
pathogens, including the clinically important Staphylococcus and Neisseria where it is 
essential [11, 12].
Crystal structures have been determined for GCYH-IA from Escherichia coli [13], humans 
[14], rat [15], and Thermus thermophilus [16], and for Zn2+- and Mn2+-metallated forms of 
GCYH-IB from Neisseria gonorrhoeae [12]. Remarkably, while both subfamilies catalyze 
the same reaction and belong to the same structural superfamily (T-fold), they share only 2 
residues in common and exhibit major differences in global structure and active site 
architecture [12]. While GCYH-IA is a unimodular, homodecameric, Zn2+-dependent 
enzyme, GCYH-IB is a bimodular, homotetrameric enzyme activated by a variety of divalent 
cations [12], with maximal activity observed with Mn2+. In both enzymes, as in all T-fold 
members, catalysis occurs at the interfaces between the T-fold subunits [12, 17]. However, 
several helical insertions and deletions near the interface render the active sites of the two 
enzymes significantly different. These differences, coupled with the occurrence of the latter 
enzyme in clinically important human pathogens that lack GCYH-IA, and thus depend 
solely on GCYH-IB for folate biosynthesis, have positioned GCYH-IB as a potential new 
antibacterial target in the folate pathway [12, 18]. These differences also led to the proposal 
that the two GCYH-I subfamilies may employ different catalytic strategies [12].
While details of the mechanism have been proposed for the type IA enzyme [14, 16, 19], the 
mechanism of the type IB enzyme has not been explicitly addressed. Here, we present 
kinetic parameters and competitive inhibition data of N. gonnorrhoae GCYH-IB, and 
describe crystal structures of two enzyme-ligand complexes that represent two states of the 
enzyme catalytic cycle: one structure is of the complex with 8-oxo-GTP, an analog of a 
reaction intermediate, and the other structure is of the complex with 
Tris(hydroxymethyl)aminomethane (TRIS), representing another intermediate previously 
postulated for the GCYH-I reaction. Additionally, we provide data on the consequences of 
site-directed mutagenesis of putative catalytic residues implicated from the crystal 
structures. Finally, we present crystallographic and biochemical evidence of specific, 
posttranslational S-nitrosylation of a conserved, catalytic cysteine residue, suggesting a role 
of the S-nitrosothiol in catalysis. The results provide insight into the catalytic strategy of 
GCYH-IB, and offer a starting point for the design of specific inhibitors against GCYH-IB.
Experimental Procedures
General
Reagents, salts and buffers were of the highest quality grade, and were purchased from 
Sigma unless otherwise noted. Millipore ultrapure water (18.2 MΩ) was used for all 
solutions. [8-14C]-GTP was purchased from Moravek. Ultra pure grade 2′-dGTP and GTP 
were from Ameresco or Sigma. 8-oxo-GTP was purchased from Jena Bioscience. 7-deaza-
GTP was purchased from Trilink Biotechnologies. Neopterin and glutathione were 
purchased from Sigma.
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Preparation of wild-type protein
Wild-type N. gonorrhoeae GCYH-IB was overexpressed as an N-terminally His6 tagged 
protein in Bl21(DE3) cells (New England Biolabs Inc.) grown in Luria–Bertani (LB) 
medium with vigorous aeration as described previously [10], and purified by Ni-NTA 
chromatography. The His6 tag was removed by cleavage with factor-Xa (New England 
BioLabs, product number P8010L) according to manufacturer's protocol, followed by 
capture of the affinity tag on Ni-NTA resin. For enzyme used for biochemical assays, the 
His6 tag-free protein was subjected to a final purification step by gel filtration 
chromatography using a Enrich SEC 650 column (Bio-Rad, Hercules, CA) pre-equilibrated 
with TRIS-free buffer containing 100 mM HEPES (pH 7.4), 100 mM KCl, and 1 mM 
dithiothreitol (DTT) or β-mercaptoethanol (BME). For enzyme used for crystallization, all 
purification steps were conducted in buffer containing 50 mM TRIS-acetate (pH 8.0), 100 
mM KCl, 5 mM ZnCl2 and 1 mM BME, and the final gel filtration step was skipped. For all 
preparations, reducing agent (DTT or BME) was kept at a concentration of 1 mM in all 
purification steps, and protein purity was confirmed to be greater than 95% by SDS-PAGE.
Enzyme activity assays
Enzymatic activities were measured using either of three different enzyme assays, the 
standard fluorescence based GTP cyclohydrolase assay that relies on post-reaction oxidation 
of the enzymatic product H2NTP to the fluorescent neopterin [10], a continuous UV-vis 
assay that measures H2NTP directly [10], and a radiochemical assay that uses [8-14C]-GTP
and measures the co-product formic acid (as [14C]-HCO2H) [10]. The fluorescence assay
were performed in 100 mM HEPES (pH 8.0), 100 mM KCl, 0.5 mM MnCl2, 1 mM MgCl2, 
and 0.5 – 5 μM of N. gonorrhoeae GCYH-IB in a total volume of 100 μL. Reactions were 
initiated by the addition of GTP (final concentration 100 μM) and incubated at 37 °C for 
50-60 minutes. Reactions were terminated by addition of 12 μL of a 1% I2, 2% KI solution 
in 1.0 M HCl to oxidize the H2NTP to neopterin. Following a 15-minute incubation at room 
temperature in the dark, excess iodine was quenched with the addition of 6 μL of 2% 
ascorbic acid, and the samples were analyzed by fluorescence spectroscopy using either a 
FluoroMax-3 instrument (Horiba Jobin Yvon Scientific), a PTI Time-Master fluorometer, or 
a Gemini XPS microplate spectrofluorometer (Molecular Devices) at λEx=365 nm. 
Emission spectra were recorded between 400 and 500 nm, and the neopterin peak at 446 nm 
was monitored. Neopterin was quantified using a linear calibration curve of the fluorescence 
signal from a pure neopterin standard.
The UV-vis assays were carried out in 100 mM HEPES (pH 8.0), 100 mM KCl, 0.5 mM 
MnCl2, 1 mM DTT, 0.5 - 5 μM enzyme, and 50 μM GTP in a final volume of 100 μL. The 
reaction was held at 37 °C and monitored over 40 minutes at a wavelength of 330 nm with a 
CARY 100 Bio UV-visible spectrophotometer (Varian). Radiochemical assays were 
performed in 100 mM HEPES (pH 8.0), 100 mM KCl, 0.5 mM MnCl2, 1 mM DTT, 0.5 - 5 
μM enzyme, and 50 μM of [8-14C]GTP (10 μCi/μmol). The reactions were incubated at 
37 °C and 50 μL aliquots were taken at 5, 10, 20, and 40 minutes. Aliquots were 
immediately quenched with 62.5 μL of 0.5 M formic acid, and loaded onto columns packed 
with 100 mg of activated charcoal pre-equilibrated with 0.1 M formic acid (pH 7.0). The 
flowthrough and a 3 mL elution of 0.1 M formic acid (pH 7.0) were collected together in a 
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scintillation vial, combined with Econo-Safe scintillation cocktail (RPI), and counted on a 
LS6000 Series Scintillation Counter (Beckman).
Determination of pH optima
The optimal pH of N. gonorrhoeae GCYH-IB was determined in a 3 component buffer 
system composed of Tris-MES-acetic acid (100-50-50 mM) over a pH range of 4.0-9.0. 
Buffers also contained 100 mM KCl, 0.5 mM MnCl2, 2 mM DTT, 50 μM GTP and 1 μM 
protein in a final volume of 100 μL. After incubating at 37 °C in the dark for 30 min, the 
reactions were terminated and analyzed by fluorescence with a Gemini XPS microplate 
spectrofluorometer (Molecular Devices) as described above.
Metal activation studies
The ability of various metal ions to support catalytic activity was examined by incubating 
the dematellated apoenzyme (2 μM), prepared as described previously [12], in the presence 
of varying concentration (0.1 μM - 4 mM) of metal chlorides (MnCl2, ZnCl2, MgCl2, NiCl2, 
CaCl2, CdCl2, CoCl2, CuCl2, CoCl3, FeCl3) in 100 mM HEPES (pH 8.0) and 100 mM KCl 
for 10 min at 37 oC. Since iron(II) readily oxidizes in the presence of oxygen, all assays 
involving iron were conducted with Fe(SO4)2 under anaerobic conditions with buffers that 
had been degassed and sparged with nitrogen prior to use. Assays were initiated upon the 
addition of GTP to a final concentration of 0.1 mM and the reactions were allowed to 
proceed at 37 °C for 30 min in the dark. Reactions were terminated and analyzed by 
fluorescence with either a PTI Time-Master fluorometer or a Gemini XPS microplate 
spectrofluorometer (Molecular Devices) as described above.
Steady state kinetic analysis of wild-type N. gonorrhoeae GCYH-IB
Steady-state kinetic measurements were conducted under initial velocity conditions with 
varying concentrations of GTP (3-50 μM) as substrate. Assays were carried out in 100 mM 
HEPES (pH 8.0), 100 mM KCl, 0.5 mM MnCl2, 1 mM DTT and 0.5 μM of protein in a final 
volume of 100 μL at 37 oC. Reactions were terminated at various time points and analyzed 
by fluorescence with either a PTI Time-Master fluorometer or a Gemini XPS microplate 
spectrofluorometer (Molecular Devices) as described above. Kinetic parameters were 
calculated from the average of minimally 4 triplicates with the Michaelis-Menten equation 
using the software Kaleidagraph 4.0 (Synergy Software, Reading, PA).
Inhibition analysis was conducted by assessing enzyme activity in the presence of various 
fixed concentrations of 2′-deoxy-GTP (0, 50, 100, 200 μM), 7-deaza-GTP (0, 15, 30, 60 
μM), or 8-oxo-GTP (0.1, 0.25, 0.5 μM). Reactions were carried out as described above in the 
presence of 1 mM DTT, 0.5 μM protein, 0.5 mM MnCl2, variable GTP concentration (3-50 
μM), and analyzed by fluorescence. The data (average of minimally 4 triplicates) were fitted 
to the equation for competitive inhibition (eq. 1)
(1)
Paranagama et al. Page 5
A
uthor M
anuscript
where ν is the initial rate of reaction, S is the varied substrate concentration, I is the inhibitor 
concentration, Ki is the inhibition constant, and V is the maximum reaction velocity.
Substrate specificity analysis
Substrate specificity was determined with various nucleotides in 100-μL reactions performed 
in the presence of 100 mM HEPES (pH 8.0), 100 mM KCl, 0.5 mM MnCl2, 1 mM DTT and 
5.0 μM of protein and incubated at 37 °C for 60 minutes. Activity with GTP was assessed by 
both fluorescence and reversed-phase HPLC, while activities with 2′-dGTP, 7-deaza-GTP or 
8-oxo-GTP as substrates were assessed by reversed-phase HPLC, as described previously 
[10, 12].
Crystallization
Crystals of the enzyme complex with TRIS were generated using the enzyme prepared in 
buffer solutions containing 50 mM TRIS-acetate (pH 8.0), 100 mM KCl, 5 mM ZnCl2 and 1 
mM BME, and concentrated to 9 mg/mL in an Amicon device. Crystals were grown at 20 °C 
by vapor diffusion in sitting drops prepared by mixing 1 μL enzyme solution and 1 μL 
reservoir solution containing 10-16% (w/v) polyethylene glycol 6000, 1-1.4 M LiCl, 50 mM 
TRIS (pH 9.0), and 50 mM TRIS-HCl (pH 7.0), and equilibrated against reservoir solution 
for 1 week.
For preparation of the complex with 8-oxo-GTP, first TRIS was removed from a sample 
containing 9 mg/mL N. gonorrhoeae GCYH-IB by dialysis against 2 L of buffer solution 
containing 50 mM HEPES (pH 7.4), 100 mM KCl, 5 mM ZnCl2, and 1 mM BME for 12 
hours. 8-oxo-GTP was then added directly to the dialyzed protein to a final concentration of 
1 mM and incubated for 30 minutes. Crystals were grown by vapor diffusion in sitting drops 
prepared by mixing 1 μL enzyme-inhibitor complex and 1 μL reservoir solution containing 
10-16% (w/v) polyethylene glycol 6000, 0.6-1.4 M LiCl, 60 mM HEPES (pH 8.2), and 40 
mM HEPES (pH 6.8). For both enzyme-ligand complexes, rhomb shaped crystals grew in 1 
week to dimensions of 0.2 × 0.2 × 0.1 mm3 and were harvested and cryo-protected in 
mother liquor containing additional 25% ethylene glycol as cryo-protecting agent, and flash-
cooled in liquid nitrogen.
X-ray data collection, structure determination and refinement
For the complex with TRIS, single-wavelength X-ray diffraction data were collected at the 
Stanford Synchrotron Research Laboratory beam line 7-1. For the complex with 8-oxo-GTP, 
data were collected at the Advanced Light Source beam line 5.0.1. All data were processed 
in the HKL2000 program suite [20]. The structures were determined using the difference 
Fourier method, and the previously determined structure of the enzyme (PDB ID 3D1T, 
[12]) as a start model after removing all heteroatoms. Initial rigid-body refinement, followed 
by restrained crystallographic refinement and solvent fitting were done using refmac-5 [21] 
and Coot [22]. Clear density corresponding to bound ligands and zinc ions could be seen in 
the active sites in both structures after rigid-body refinement. Zn2+ and ligands were 
modeled in the density and the structures were subjected to several rounds of restrained 
maximum-likelihood refinement of coordinates and temperature factors, iterated with 
solvent modeling.
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Preparation of site-directed mutants
Point mutagenesis was carried out on pSAB-8-142 (N. gonorrhoeae GCYH-IB gene cloned 
in pET-30 Xa/LIC vector [10]) using the Q5® Site-Directed Mutagenesis Kit (NEW 
ENGLAND Biolabs Inc.) or the QuikChange™ site-directed mutagenesis kit (Stratagene). 
The Glu152 residue was mutated to Ala (GAG→GCT). Glu243 was mutated to Ala 
(GAG→GCT). His246 was mutated to Ala (CAC→GCT), Asp (CAC→GAC), Gln 
(CAC→CAG), Asn (CAC→AAC), and Lys (CAC→AAG). Cys149 was mutated to Ser 
(TGT→TCT) and Ala (TGT→GCC). The primers used for the mutations are listed in 
Supplementary Table 1. The resulting DNA constructs were confirmed to be correct and in 
frame by sequencing (at Genewiz, Inc, South Plainfield, NJ, or at the Portland State 
University-Keck Genomic Facility, Portland, OR). The His246Ala and Glu243Ala mutants 
were overexpressed in E. coli DH5α competent cells, and all other mutants were 
overexpressed in E. coli BL21(DE3) as described for the wild-type enzyme. All mutant 
proteins were purified by Ni-NTA and size-exclusion chromatography as described for the 
wild-type enzyme. Purity was verified to be greater than 95% by SDS-PAGE.
Enzymatic assays of all GCYH-IB mutants and wild-type enzyme were monitored via both 
UV-vis and radiochemical assays as described above. Initial velocities were calculated from 
non-linear fits of the reaction progress curves.
Test for in vitro formylation of GCYH-IB
To test for formylation of GCYH-IB 50 μL reactions containing 100 mM HEPES (pH 8.0), 
100 mM KCl, 0.5 mM MnCl2, 1 mM DTT, and 100 μM [8-14C]GTP (10 μCi/μmol) were
prepared. Reactions were initiated with either 25 μM recombinant His6-tagged N. 
gonorrhoeae GCYH-IB that possessed a modified Cys149 residue, or 25 μM enzyme that 
had been subjected to the GSH treatment described below. The reactions were incubated in 
1.5 mL Eppendorf tubes at 37°C for 40 minutes before the addition of 20 μL of Ni-NTA 
resin and a further 30 minute room-temperature incubation with gentle mixing. The 
reactions were centrifuged for 5 minutes at 500g and the supernatant saved. The Ni-NTA 
resin pellets were subjected to 10 washes with 200 μL of buffer (100 mM HEPES (pH 8.0), 
100 mM KCl) with centrifuging for 2 minutes at 500g between each wash. The supernatant, 
the ten washes, and the 1.5 mL reaction tube holding the Ni-NTA resin pellet (but with cap 
removed) were collected in 5 mL scintillation vials and combined with Econo-Safe 
scintillation cocktail (RPI). Counting was performed on a Hidex 300 SL scintillation counter 
(Hidex) using MikroWin software (Mikrotek Laborsysteme GmbH).
In vitro de-nitrosylation of GCYH-IB
To prepare de-nitrosylated GCYH-IB, a sample containing 600 μg of freshly purified, active 
enzyme was made at a concentration of 28 μM in buffer containing 100 mM HEPES, 100 
mM KCl, and 0.5 mM MnCl2 (pH 8.0). Glutathione (GSH) was freshly dissolved in water 
and added to the protein sample to a final concentration of 280 μM and was incubated for 30 
minutes in the dark. Excess GSH was removed in two buffer exchange steps by loading onto 
Zeba Spin Desalting Columns (MWCO 7,000 Da, ThermoFisher Scientific, Waltham, MA) 
pre-equilibrated in buffer containing 100 mM HEPES (pH 7.4), and 100 mM KCl; and 
centrifuging at 1000 g for 2 minutes. The resulting GSH-treated protein was immediately 
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assayed for activity using the fluorescence assay described above, and for its state of 
nitrosylation using the iodoTMT-switch assay (vida infra).
IodoTMT switch assay
This assay was carried out using the Pierce™ S-nitrosylation Western Blot Kit 
(ThermoFisher Scientific, Waltham, MA) following a modified version of the manufacturer's 
protocol. Briefly, a 100 μL sample containing 1 μg/μL protein in HENS buffer was prepared, 
and 5 μL of a 100 mM solution of the irreversible blocking agent N-ethylmaleimide (NEM, 
prepared in ultrapure water) were added to block the protein free thiols. After vortexing 
vigorously and incubating for 30 minutes at 50 °C, excess NEM was removed in two buffer 
exchange steps using Zeba Spin Desalting Columns (MWCO 7,000 Da). The protein was 
then precipitated by adding 6 volumes of cold acetone (pre-equilibrated at -20 °C) and 
incubating for one hour at -20 °C. The precipitated protein was pelleted by centrifuging at 
10,000 g for 10 minutes, and the pellet was re-suspended in 100 μL of HENS buffer and 
divided into two 50-μL batches. To one batch, 4 μL of 1.0 M sodium ascorbate (prepared in 
ultrapure water) and 1 μL of 20 mM iodoTMT6-126 labeling reagent (iodoTMT) were 
added to reduce and label the nitrosylated thiols, respectively. (The final protein, ascorbate, 
and iodoTMT concentrations were 30 μM, 75 mM and 0.4 mM, respectively). For a negative 
control, the second batch was treated similarly except that the ascorbate was replaced with 
ultrapure water. Following incubation for 2 hours at room temperature, excess labeling 
reagent and ascorbate were removed in two buffer exchange steps using Zeba Spin Desalting 
Columns. The proteins were then precipitated by adding 6 volumes of cold acetone and 
incubating over night at -20 °C, followed by centrifugation at 10,000 g for 10 minutes. The 
precipitated proteins were each re-suspended in 50 μL of HENS buffer and analyzed by 
Western blotting (see below). All steps were performed in the dark and the protein 
concentration after each precipitation/resuspension step was determined using a Bradford 
assay, absorption at 280 nm, and BSA-calibrated SDS-PAGE on an Any kD Mini-Protean 
TGX gel (Bio-Rad, Hercules, CA).
Western blot analysis of iodoTMT-labeled proteins
Equal amounts of labeled proteins were loaded on a denaturing Mini-Protean TGX precast 
gel (Bio-Rad, Hercules, CA) and electrophoresed without any reducing agents for 15 
minutes at 300 V. The proteins were then transferred to a PVDF membrane (0.45 μm, 
ThermoFisher Scientific) by electroblotting for 48 mins at 60 V in a wet transfer apparatus 
(Bio-Rad, Hercules, CA). The membrane was blocked by incubating for 5 hours in 5 mL 
TRIS-Buffered Saline and Tween (TBST buffer: 20 mM TRIS, 150 mM NaCl and 0.1% 
Tween 20, pH 7.5) containing 2% BSA, and immunolabeled by incubation overnight in 
TBST solution containing mouse anti-TMT monoclonal antibody (IgG2b, ThermoFisher 
Scientific, product number 90075) at a dilution of 1:500. Following 5 washes in TBST, the 
membrane was probed with goat anti-mouse IgG-horseradish peroxidase conjugate antibody 
(ThermoFisher Scientific, product number Ab97040) at 1:10,000 dilution for one hour. 
Subsequently, the membrane was washed 5 times with TBST and developed with 
SuperSignal West Pico Chemiluminescent Substrate (ThermoFisher Scientific). All steps 
were carried out at room temperature. To verify equal loading of proteins, a second, identical 
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SDS-PAGE was performed in parallel on the same samples and that gel was stained with 
Coomassie to visualize total protein.
Oxidation of GCYH-IB by hydrogen peroxide (H2O2)
A 20-μL sample of each of the freshly purified GCYH-IB (verified to be S-nitrosylated by 
the iodoTMT assay as described above), and the GSH-treated GCYH-IB was prepared in 
assay buffer (100 mM HEPES (pH 8.0), 100 mM KCl, 0.5 mM MnCl2, 1 mM MgCl2) at a 
final protein concentration of 25 μM. H2O2 was added to a final concentration of 0.25 mM 
and the reactions were incubated in the dark for 5, 10, 15, 30 and 60 seconds before addition 
of catalase (from bovine liver, Sigma-Aldrich) to a final concentration of 600 U/mL to 
quench excess H2O2. The samples were immediately assayed for H2NTP production using 
the fluorescence assay.
Results
Biochemical characterization of GYCH-IB from N. gonorrhoeae
We previously reported the biochemical properties of GCYH-IB from B. subtilis [12], and 
the N. gonorrhoeae enzyme exhibited similar characteristics. In particular, the N. 
gonorrhoeae GCYH-IB shows optimal activity broadly between pH 8.0 – 8.5 in HEPES 
buffer (data not shown), and is able to utilize a variety of metals for catalysis 
(Supplementary Table 2), exhibiting maximal activity in the presence of 0.5 mM Mn2+.
Kinetic parameters and competitive inhibition of N. gonorrhoeae GCYH-IB with substrate 
analogs
Steady-state kinetic analysis of recombinant N. gonorrhoeae GCYH-IB, overexpressed in E. 
coli and freshly purified, provided a Km of 9.15 ± 0.67 μM and kcat of 0.0159 ± 0.0013 
min-1 with GTP as substrate, similar to the previously reported kinetic parameters for the 
Bacillus subtilis enzyme (Km of 9.87 μM and kcat of 0.0011 min-1 [12]). The substrate
analogs 2′-dGTP, 7-deaza-GTP and 8-oxo-GTP were investigated for their effects as 
inhibitors, and all three analogs gave competitive inhibition patterns with respect to GTP, but 
only 8-oxo-GTP functioned as a potent inhibitor with a Ki/Km of 0.022, which is 300 and 
1000 fold lower than the Ki/Km for 7-deaza-GTP and 2′-dGTP, respectively (Table 1, Fig. 
2). These analogs were also investigated as alternate substrates, but reversed-phase HPLC 
analysis of incubations with the enzyme failed to detect any products. Indeed, in each case 
only a single peak corresponding to the starting nucleotide was observed in the HPLC 
chromatogram (data not shown), indicating that they were not turned over by the enzyme.
Crystal structure of N. gonnorrhoae GCYH-IB in complex with 8-oxo-GTP
The enzyme complex with the inhibitor nucleotide 8-oxo-GTP crystallized in space group 
C2221. The structure was determined by difference Fourier calculation using model phases 
calculated from the previously determined crystal structure of the inhibitor-free enzyme 
(PDB ID 3D1T [12]), and was refined at a resolution of 2.77 Å. Data collection and 
structure refinement statistics are listed in Table 2. The structure reveals the GCYH-IB 
homotetramer [12] with half a tetramer (subunits A and B) comprising the asymmetric unit 
(Fig. 3). Each subunit (257 amino acids) is composed of two tunnel-fold (T-fold) modules 
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with the architecture characteristic of bimodular T-fold enzymes. In each subunit, an eight-
stranded tightly twisted antiparallel β-sheet is backed by four antiparallel α-helices. The β-
sheets from the two adjacent subunits form a continuous 16-stranded β-barrel, and two 
barrels join together head-to-head to form a central tunnel. The enzyme active sites are 
located at the interfaces between subunits.
Difference electron density maps reveal a bound zinc ion and 8-oxo-GTP molecule in two of 
the four active sites in the biological tetramer (Fig. 3 and Fig. 4A). The other two active sites 
are more exposed to solvent in the crystal lattice and are unoccupied. The inhibitor 
nucleotide is in the syn conformation and its binding pocket lies at the interface between 
three subunits, two from the same β-barrel (subunits A and B), and one from the opposite β-
barrel (subunit B′, Fig. 4). The purine moiety of the inhibitor is inserted into the pocket, 
while the ribosyl and triphosphate moieties lie on the surface near the pocket entrance.
The Zn2+ ion binds at the interface between opposite β-barrels and is coordinated in a 
distorted tetrahedral geometry by the Sγ atom of Cys147, the Nε2 of His159, the Oε2 of 
Glu201 (all invariant residues in the type IB enzymes), and the O8 atom of 8-oxo-GTP (Fig. 
4). The purine moiety of the inhibitor is sandwiched between Phe214 (from subunit B) and 
Met60 (from subunit A), both conserved hydrophobic residues in the GCYH-IB family. The 
purine ring is anchored to the pocket by side chain and backbone interactions with Glu216, 
Val215, and Thr58; while the purine N7, which is protonated in 8-oxo-GTP, donates a 
hydrogen bond to the side chain of the invariant residue Glu243 (Fig. 4). The latter 
interaction indicates a role for Glu243 in the protonation of N7 of the GTP substrate, an 
event necessary for the first hydration step of the GCYH-I reaction. Consistent with this 
interpretation, replacement of N7 with a carbon in the 7-deaza-GTP analog results in 
compromised binding (Table 1).
The ribose ring adopts a C3′-endo pucker conformation, a common conformation in 
nucleosides and nucleotides in general [23]. Two key interactions are seen with the ribosyl 
moiety: 1) The ribosyl 2′-hydroxyl group is coordinated via a hydrogen bond (H-bond) by 
the carboxylate Oε1 of Glu201 from the adjacent β-barrel (thus, Glu201 bridges between the
metal ion and the inhibitor). The importance of this interaction for substrate binding is 
demonstrated by the 24-fold higher Ki value of 2′-deoxyGTP relative to the Km of GTP 
(Table 2). 2) The C2′ atom is within contact distance from the Sγ atom of the conserved
residue Cys149. Close inspection of the difference electron density maps revealed extra 
density extending from the Sγ atom of Cys149, corresponding to a nitrosyl group (Fig. 4A). 
Although the resolution of this structure does not permit distinguishing a nitrosyl from a 
formyl group, the latter was ruled out based on the higher resolution Tris-bound structure 
and a biochemical test (vida infra). The S-nitrosothiol adopts a staggered anti conformation 
with a Cβ-Sy-N-O dihedral angle of 103°. As shown by Zhao and Houk [24], this 
conformation suggests a stable reduced thionitroxide radical form in which a hydrogen is 
bonded to the nitrogen atom (Cβ-Sy-NH-O). Consistent with this interpretation, the putative 
radical is stabilized in the structure by interaction with the conserved Arg198 side chain 
protruding into the active site from the opposite β-barrel (Fig. 4B). Notably, the nitrosyl 
group is present even though the protein was purified and crystallized in the presence of 1 
mM DTT/βME, consistent with a highly stable thionitroxide form. S-nitrosylation of 
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Cys149 is also seen in the unoccupied active sites, and with a similar staggered 
conformation (dihedral angle ∼ 122°). The triphosphate tail of 8-oxo-GTP is stabilized by 
H-bonds with conserved residues His59, Ser61 and Arg62.
Bound TRIS molecule mimics a reaction intermediate
We also determined a high resolution (1.9 Å) crystal structure of the enzyme prepared and 
crystallized in the presence of TRIS buffer. In this structure, a bound TRIS molecule is seen 
coordinating the Zn2+ ion in two of the four active sites in the homotetramer. The Zn2+ ion 
forms a trigonal bipyramidal coordination shell with its five ligands: the Sγ atom of Cys147, 
the Oε2 atom of Glu201 from subunit B′, and the amino group of bound TRIS in the 
equatorial plane; and the O3 hydroxyl group of TRIS, and the Nε2 atom of His159 as axial 
ligands (Fig. 5). This rather unusual zinc coordination geometry is common in proposed 
transition states of metalloenzymes [25]. Cys149 is also found S-nitrosylated in this 
structure. To rule out the possibility that the modification may be S-formylation associated 
with the formate-releasing activity of the enzyme, we modeled a formyl group in the 
electron density and observed the resulting temperature factors after structure refinement. 
The refined temperature factor for the formyl carbon atom was 8 Å3 lower than the 
temperature factor of the Sγ atom, indicating that the electron density is under-represented 
by the model in this case. In contrast, when modeled as a nitrosyl group, the refined 
temperature factor of the nitrosyl nitrogen atom is within the expected range for optimal fit 
to the density (< 3 Å3 lower than the temperature factor of the Sγ atom). In this structure, 
the S-nitrosyl group is in a syn conformation and exhibits a planar geometry with a small 
Cβ-Sγ-N-O dihedral angle of ∼24°, close to the geometry of small-molecule S-nitrosothiols 
[26-31], indicating that it is the oxidized form Cβ-Sγ-N=O [24].
Superposition of the TRIS-bound structure with the 8-oxo-GTP-bound structure (r.m.s.d. of 
0.27 Å over 237 of subunit B Cα atoms, subunit A is much less ordered) reveals that the 
bound Tris molecule is reminiscent of a tetrahedral transition-state intermediate proposed to 
occur in the GCYH-I-catalyzed reaction prior to breakage of the C8-N7 bond and release of 
formate from GTP (Fig. 6) [16]. In this intermediate, C8 is the tetrahedral center that is 
imitated by the tetrahedral carbon atom of TRIS. In the superposition, the N atom of TRIS 
occupies the same site as the O8 atom of 8-oxo-GTP, thus mimicking the state of the metal-
coordinated hydroxyl ion after it performs the first nucleophilic attack on the C8 atom of the 
substrate. The C2 carbon of TRIS mimics the state of the second water molecule after it 
performs the second nucleophilic attack on C8. Notably, the O2 atom of TRIS makes a 
hydrogen bond with the conserved side chain His246 (Fig. 5 and Fig 6), and the position of 
O2 may represent the position of the second nucleophilic water molecule just before its 
attack on C8 and formation of the tetrahedral center. Further, the metal-coordinating O3 
atom of TRIS occupies an analogous position to the 2′-OH of 8-oxo-GTP, thus may 
represent the position of the 2′-OH of the substrate during a late step in the reaction after 
opening of the ribose ring. Finally, a 6 Å-wide water-filled cavity located behind the purine 
binding pocket is seen in both structures and may serve as the putative binding site for the 
formate molecule released in the early steps of the GTP cyclohydrolase reaction (Fig. 6).
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The crystal of the complex with TRIS was grown under the same crystallization conditions 
and using the same sample preparation conditions as the previously described structure with 
PDB ID 3D1T [12] and a resolution of 2.2 Å. Re-refinement of PDB ID 3D1T also revealed 
a bound TRIS molecule in the active site and S-nitrosylated Cys149, and was therefore 
replaced with the higher resolution structure presented here.
S-nitrosylation of GCYH-IB is site specific and preserves enzyme activity
The structural observation of S-nitrosylation of a catalytic active-site cysteine residue 
prompted us to investigate this post-translational modification biochemically. First, we 
confirmed its presence in the freshly purified enzyme in solution using the iodoTMT-switch 
assay, and investigated the effect of the SNO on enzyme activity. In the iodoTMT-switch 
assay, the free thiols in the protein are first blocked using the irreversible blocking agent 
NEM. The S-nitrosylated cysteines are then reduced with ascorbate, and the newly formed 
free thiols are labeled with iodoTMT. The labeled thiols are then detected and quantified by 
Western blot analysis using an anti-TMT antibody. To elucidate the effect of S-nitrosylation 
of Cys149 on enzyme activity, we denitrosylated the freshly purified wild-type enzyme by 
treating it with reduced glutathione (GSH, a widely used method for denitrosylation of 
proteins [32]) and, after removal of excess GSH, assayed the resulting denitrosylated form 
for H2NTP production activity using the fluorescence assay. To eliminate the effect of 
possible glutathione chelation of the catalytic metal, the GSH-treated enzyme was incubated 
in assay buffer containing 0.5 mM metal before adding substrate. While the GSH-treated 
enzyme was fully denistrosylated, as confirmed by the iodoTMT-switch assay (Fig. 7A), its 
activity was found to be comparable to that of the untreated enzyme, with only 20% 
reduction (Fig. 7B), indicating that Cys149 supports catalysis in both the nitrosylated and 
reduced states.
As further proof that the Cys149 modification occurred as a consequence of nitrosylation, 
and not formylation in the course of enzymatic turnover, we probed for the possibility of 
formyl transfer from GTP with reactions containing [8-14C]GTP followed by capture of the 
protein on Ni2+-NTA resin and liquid scintillation counting. To test for formylation that 
might occur during each turnover (with consequent loss of starting formyl group) as well as 
advantageous formylation that might occur to unmodified Cys149 and then be retained in 
subsequent turnovers, we tested enzyme that possessed modification of Cys149 and enzyme 
that had been treated with GSH as described above, and thus lacked modification. In no case 
did we see radioactivity above background associated with protein fractions (data not 
shown), allowing us to conclude that no transfer of a formyl group to the protein occurred in 
any of the reactions. In these experiments the background radioactivity corresponded to the 
calculated radioactivity that would be observed for ∼0.5% labeling.
In addition to Cys149, N. gonnorrhoae GCYH-IB contains two other cysteine residues in 
each subunit: the metal coordinating Cys147 in the active site, and Cys190 located in a 
partially solvated hydrophobic pocket 12 Å away from the active site. In the crystal 
structures, only Cys149 is seen S-nitrsoylated. To confirm this observation, we assessed the 
nitrosylation state of the Cys149Ala mutant using the iodoTMT-switch assay. The results 
show that while the fully active, wild-type protein in solution and as purified from E. coli is 
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S-nitrosylated, the Cys149Ala mutant protein purified under the same conditions lacks any 
S-nitrosylated thiols (Fig. 7A). These results demonstrate that the observed S-nitrsoylation 
of GCYH-IB occurs posttranslationally during heterologous expression in E. coli and that it 
is specific to Cys149. Although the physiological relevance of the observed S-nitrosylation 
of GCYH-IB in a heterologous system is unclear, the specificity of the nitrosylation to a 
conserved and essential active-site cysteine, and the direct interaction of the thionitroxide 
group with the substrate analog seen in the crystal structure suggest that it may participate 
directly in catalysis (see details in the discussion).
Role of Cys149, Glu152, Glu243, and His246 in catalysis
Of the active site residues that interact with 8-oxo-GTP and TRIS in the structures, three 
residues make contacts that suggest a direct role in catalysis. These residues are Glu243 and 
Cys149, which interact with the guanine imidazole ring and ribosyl moiety of 8-oxo-GTP, 
respectively, and His246, which coordinates the O2 atom of the transition state mimic TRIS. 
Additionally Glu152 is positioned where it might serve as an acid/base residue to modulate 
the protonation state of Cys149. Glu243, and His246 are conserved residues in all GCYH-IB 
sequences, whereas Cys149 is only conserved in bacterial GCYH-IB sequences and Glu152 
is present in only a subset of bacterial sequences (see Supplementary Fig. 1). To investigate 
the role of these residues in catalysis, we prepared site-directed mutants of Cys149, Glu152, 
Glu243, and His246, and measured the abilities of the mutant proteins to catalyze formation 
of the reaction product H2NTP, as well as their abilities to catalyze the early steps in the 
reaction leading to formate release from GTP. For the former activity we monitored the 
formation of H2NTP using a fluorescence assay as well as a UV-vis continuous assay 
measuring the absorbance of H2NTP at 330 nm. For the latter activity, we monitored release 
of [14C]-formate from [8-14C]GTP using a radiochemical assay. Notably, studies with the IA 
enzyme have demonstrated the ability to uncouple the early steps in the reaction from the 
late steps by independently measuring formate and H2NTP formation, and showing that 
some mutants compromised in H2NTP formation are able to efficiently catalyze the early 
steps in the reaction and release formate along with the intermediate 2,5-diamino-(6β)-
ribosylamino-4(3H)-pyrimidinone 5′-triphosphate (DRPT) [33]. All mutants were 
overexpressed in E. coli and freshly purified under the same conditions used to purify the 
wild-type enzyme. The structural integrity of the mutant proteins was checked by size 
exclusion chromatography and their elution profiles were identical to that of the wild-type 
enzyme, showing a single peak corresponding to an intact homotetramer with apparent 
molecular weight of 135,000 Da (Supplementary Fig. 2).
With the exception of the Glu152 mutant, which exhibited ∼20% of the wild-type activity, 
all of the alanine mutants exhibited impaired ability to carry out full catalytic turnover to 
produce H2NTP, with activities <1% that of the wild-type enzyme (Table 3, Supplementary 
Fig. 3). In contrast, when assaying for production of [14C]-formate only the Glu152Ala and 
Glu243Ala mutants showed a similarly impaired ability in the production of formate, while 
the His246Ala mutant exhibited an almost 3x higher rate of formate production than H2NTP, 
and the Cys149Ala mutant, for which we were unable to detect H2NTP production, 
exhibited a robust rate of formate production roughly 10% that of the wild-type enzyme. 
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Consistent with this pattern, the Cys149Ser mutant displayed activity for H2NTP formation 
∼3% that of wild-type, and for formate production almost 20% that of wild-type.
The observed catalytic activities of the Glu243 and Cys149 mutants suggest roles in the 
early and late stages of the chemical mechanism, respectively, conclusions consistent with 
the crystallographic information from the GCYH-IB structures containing 8-oxo-GTP and 
TRIS. In contrast, mutation of His246, which interacts with the O2 atom of TRIS in the 
TRIS-bound structure, an interaction suggestive of the transition state leading to formate 
release (vide supra) in an early step in the reaction, results in enhanced production of 
formate relative to H2NTP.
To further probe the role of His246, we constructed His246 mutants substituted with Asn, 
Gln, Asp and Lys and measured their ability to catalyze the formation of formate and 
H2NTP. All of these mutants were compromised in their ability to catalyze the formation of 
H2NTP (Table 3), with only the Asp and Gln mutants capable of complete turnover. 
Remarkably, all of the mutants were capable of modest to robust production of formate, with 
the Asp and Gln mutants capable of formate production at a rate >65% that of the wild-type 
enzyme (Table 3).
S-nitrosylation of GCYH-IB does not provide protection against oxidation
Since the nitrosylated cysteine is a catalytic residue, we interrogated the possibility of the 
SNO modification serving a protective role against oxidative inactivation of the enzyme. In 
this experiment, the activities of the freshly purified (S-nitrosylated) GCYH-IB and the 
GSH-treated (denitrosylated) enzyme were monitored following incubation with 0.5 mM 
hydrogen peroxide for 30 seconds. The activities of both the nitrsoylated and denitrosylated 
enzyme dropped by the same extent and rate with exposure time to H2O2 (data not shown), 
indicating no observable protection by the SNO against oxidative inactivation.
Discussion
Comparison with GCYH-IA
8-oxo-GTP is the most potent inhibitor of GCYH-IB identified to date, exhibiting a Ki = 150 
nM with the N. gonorrhoeae enzyme. Notably, however, inhibition is more modest than 
observed with GCYH-IA, which exhibits a Ki = 5.4 nM with the enzyme from T. 
thermophilus [16], almost 28-fold lower than the observed Ki for GCYH-IB. Comparison 
with the crystal structure of the ternary complex of T. thermophilus GCYH-IA with Zn2+
and 8-oxo-GTP (PDB ID 1WUQ) [16] reveals that the two enzymes bind 8-oxo-GTP in the 
same general orientation and provide the same distorted tetrahedral geometry for 
coordinating the Zn2+, with the O8 atom of 8-oxo-GTP acting as the fourth and axial ligand 
(Fig. 8A), consistent with a similar role for the metal ion in their catalytic mechanisms.
Both enzymes make the same number of H-bonds (five direct and one water-mediated H-
bonds) and similar hydrophobic interactions with the guanidine ring of 8-oxo-GTP. 
However, their recognition of the ribosyl and triphosphate moieties is different (Fig. 8B). 
First, the two enzymes favor different orientations of the ribosyl moiety relative to the base, 
as achieved through rotation around the β-N9-glycosidic bond. In GCYH-IB, the bound 
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nucleotide's chi (χ) torsion angle (defined by O4′-C1′-N9-C4) is 34°, whereas in GCYH-IA 
it is -106° (averaged over all active sites), amounting to a counterclockwise rotation around 
the glycosidic bond of 140° in the GCYH-IB-bound conformer relative to the GCYH-IA-
bound conformer. This rotation is stabilized by enzyme-specific interactions with the 2′- and 
3′-hydroxyl groups. In the GCYH-IB-bound conformer, O2′ and O3′ point toward the B 
and B′ subunits and O2′ interacts with the -IB specific and invariant side chain Glu201, 
whereas in the GCYH-IA-bound conformer these hydroxyl groups point toward subunit A 
and are coordinated by the -IA specific and invariant Ser133 (in T. thermophilus numbers, 
Fig. 8B). Second, the two enzymes accommodate different conformers of the ribose ring in 
their active sites; in GCYH-IB the ribose adopts the common C3′-endo conformation, while 
in GCYH-IA it adopts a rare C1′-exo conformation [16]. Third, in GCYH-IB, the 
triphosphate tail binds in a shallow pocket formed by residues from one subunit, whereas in 
GCYH-IA this pocket is deeper and is formed by basic side chains from all three interfacing 
subunits (Fig. 8C).
Overall, the inhibitor makes only 15 H-bonds with the GCYH-IB active site (14 direct and 
one water-mediated) versus 20 H-bonds with GCYH-IA (17 direct and 3 water-mediated), 
and 4 of the 5 additional bonds are with triphosphate atoms. Thus, the apparent difference in 
Ki exhibited by 8-oxo-GTP to the two enzymes appears to be mostly due to differences in 
recognition of the triphosphate tail.
In summary, GCYH-IA and GCYH-IB exhibit similarities in their binding to the purine 
moiety of the substrate analog, but differ in binding the ribosyl and triphosphate groups. 
These differences may be employed in the design of improved inhibitors specific for GCYH-
IB.
S-nitrosylation of GCYH-IB
S-nitrosylation is a nitric oxide (NO) mediated posttranslational modification that regulates 
protein function [34-38]. Our structural and biochemical data show that GCYH-IB is S-
nitrosylated at an essential, active-site catalytic cysteine and that the nitrosylated enzyme is 
active, if not more active than the denitrosylated form. Although many enzymes are known 
to be reversibly inactivated by S-nitrosylation of an active-site cysteine (e.g., the human 
mitochondrial caspases [39], protein tyrosine phosphatases [40], mammalian methionine 
adenosyltransferases [41], and dimethylarginine dimethylaminohydrolases [42], for partial 
review see [43]), to our knowledge, there are no reported examples of enzymes in which S-
nitrosylation of a catalytic cysteine residue maintains (or enhances) activity.
S-nitrosylation of active site cysteines has also been shown to protect some enzymes from 
oxidative inactivation (e.g., protein tyrosine phosphatase IB [44] and galectin-2 [45]), 
however we did not detect such protection of the S-nitrosylated N. gonorrhoeae GCYH-IB 
from oxidative inactivation by H2O2. This could be due to oxidation of one or both of the 
other two cysteine thiols in the protein, especially the metal ligand Cys147, thus 
compromising the structural integrity of the enzyme tetramer. Consistent with this 
interpretation, purification of the enzyme in the absence of DTT results in a destabilized 
tetramer (as detected by gel filtration chromatography) and subsequent loss of activity 
(Supplementary Figure 4). Additionally, GCYH-IB is transcriptionally upregulated in N. 
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gonorrhoeae when the organism is subjected to oxidative stress by exposure to peroxide 
[46].
The precise source of the NO that posttranslationally modifies GCYH-IB during 
heterologous expression in E. coli remains unclear. S-nitrosylation in E. coli has been shown 
to be a prominent feature of anaerobic respiration on nitrate where the nitrate reductase 
NarG acts as the major source of S-nitrosylating activity [37]. However, in the present study, 
we did not provide the E. coli cultures with exogenous nitrate, and the cultures were grown 
aerobically. In general, biological S-nitrosylation of proteins occurs through 1) an 
autocatalytic mechanism in which the protein hydrophobic core accumulates NO and 
accelerates its oxidation to the more reactive N2O3 causing S-nitrosylation of a nearby 
cysteine thiol within the protein interior [47], or 2) oxidation of NO to the nitrosonium 
cation (NO+) by reaction with a transition metal or transfer from another S-nitrosylated 
protein or small S-nitroso compounds (e.g., S-nitrosoglutathione) to a solvent-exposed thiol 
(transnitrosylation) [48]. The nitrosylated cysteine in GCYH-IB resides in a short helix on 
the surface of the protein, completely exposed to solvent, consistent with transnitrosylation, 
not autocatalysis.
Proposed catalytic mechanism of GCYH-IB
A chemical mechanism has been proposed for the GCYH-IA enzyme based on 
crystallography and a variety of biochemical studies, including mutagenesis, NMR analysis 
and transient state kinetics [14, 16, 19, 33, 49-52]. In the early steps in the mechanism, the 
reaction is initiated with reversible hydrolysis of GTP at C8 via nucleophilic attack of a zinc 
activated water molecule and cleavage of the C8-N9 bond to form an N-formyl intermediate, 
which subsequently undergoes a second hydrolysis reaction at C8 resulting in the cleavage 
of the C8-N7 bond and elimination of C8 as formate. In the second half of the reaction the 
ribosyl moiety undergoes ring opening and an Amadori rearrangement followed by 
cyclization and loss of the 2′-oxygen as H2O to give H2NTP.
Our biochemical and structural data are consistent with GCYH-IB facilitating the same 
chemical steps as GCYH-IA. 8-oxo-GTP, 7-deaza-GTP and 2′-deoxyGTP do not act as 
substrates for GCYH-IB, consistent with the proposed GCYH-IA chemical mechanism in 
which oxidation of C8 to the carbonyl state and protonation of N7 (i.e. 8-oxo-GTP), 
although formally analogous to the N-formyl intermediate (III, Fig. 9A), precludes the 
second nucleophilic attack of water due to the reduced electrophilicity of C8 as a 
consequence of electron delocalization in the 8-oxo-guanine ring. Likewise, replacing N7 
with a carbon (i.e. 7-deaza-GTP) prevents the initial hydrolysis step due to reduced 
electrophilicity of C8. Finally, the absence of the 2′-OH (i.e. 2′-deoxyGTP) prevents the 
Amadori rearrangement necessary for the formation of the pterin ring system (VIII to X, 
Fig. 9B).
However, differences in the active-site architecture and the different modes of recognition of 
the ribosyl moiety by the two enzymes suggest that they utilize different catalytic strategies. 
Our proposal of the GCYH-IB catalyzed mechanism is shown in Figure 9. In this proposal, a 
water molecule coordinated to the metal is first deprotonated by Glu243 to produce a metal-
coordinated hydroxyl ion (I, Fig. 9A) that carries out nucleophilic attack at C8, accompanied 
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by protonation of N7 by Glu243 (II, Fig. 9A). In contrast, in GCYH-IA, protonation of N7 is 
carried out by a water molecule [16] coordinated to a His residue. Decomposition of the 
tetrahedral intermediate and breakage of the C8-N9 bond (II, Fig. 9A) is mediated by a 
bound water molecule (W2 in 8-oxo-GTP bound structure, Fig 4A), yielding the 
intermediate 2-amino-5-formylamino-(6β)-ribosylamino-4(3H)-pyrimidinone 5′-
triphosphate (AFRPT, III, Fig. 9A). This intermediate has been experimentally verified in 
the reaction catalyzed by GCYH-IA [33, 50] and is mimicked by 8-oxo-GTP except for the 
out of plane geometry of the CHO group relative to the base.
The water molecule (W2), H-bonded to His246, is deprotonated by Glu243 to yield a second 
nucleophilic hydroxyl ion that attacks the out of plane electrophilic carbonyl C8 to produce a 
second tetrahedral intermediate (IV, Fig. 9A). This intermediate is mimicked by TRIS in the 
TRIS-bound crystal structure of GCYH-IB (Fig. 5). Collapse of this intermediate coupled 
with protonation of N7 by Glu243 and bond cleavage between N7-C8 produces formic acid 
and the intermediate 2,5-diamino-(6β)-ribosylamino-4(3H)-pyrimidinone 5′-triphosphate 
(DRPT, V, Fig. 9A) [8].
Ring opening of the ribose moiety is facilitated by protonation of the ring oxygen by a water 
molecule coordinated to His246 coupled with Schiff base formation at C1′-N9 (VI, Fig. 
9B). Ring opening facilitates a conformational rearrangement that allows the 2′-hydroxyl 
group to displace formate from the metal, a process facilitated by Glu201, which is seen H-
bonded to the 2′-hydroxyl in the 8-oxo-GTP-bound structure (Fig. 4). The fate of the 
formate is unclear; the presence of a water-filled cavity behind 8-oxo-GTP (Fig. 6) suggests 
that formate may be trapped there until the end of the catalytic cycle. Deprotonation of C2′ 
by Cys149 (VII, Fig. 9B) yields the enol-enamine and the protonated Cys149 thiol (VIII, 
Fig. 9B). The proximity of the carboxyl group of Glu152 suggested that the this step might 
be facilitated by proton transfer from Cys149 to Glu152, but the mutagenesis data, in which 
activity for the Glu152Ala mutant was decreased by only ∼75% in both assays, does not 
support such a role in catalysis. Glu201, then deprotonates the 2′-OH with protonation at 
C1′ by Cys149 (VIII, Fig. 9B) to give a C2′ keto group (IX, Fig. 9B). Subsequent 
nucleophilic attack by N7 on the electrophilic keto carbonyl at C2′ is facilitated by 
deprotonation at N7 by Glu243 and protonation of the carbonyl by Glu201, giving the 
bicyclic pterin ring system (X, Fig. 9B). Dehydration coupled with imine formation then 
occurs with protonation of the OH group by Glu243, forming dihydroneopterin triphosphate 
(H2NTP).
The proposed mechanism is consistent with all of the mutagenesis and crystallographic data. 
Specifically, mutation of Glu243 essentially abolishes both the formate releasing activity as 
well as complete turnover to H2NTP, as is expected for a residue involved in the early steps 
of the reaction. Replacement of Cys149 with either Ala or Ser removes a base necessary for 
initiation of the Amadori rearrangement, thus precluding the formation of the pterin ring. 
However, mutation does not prevent the hydrolytic steps in the reaction as these occur prior 
to the direct participation of Cys149. Nevertheless, there is a decrease in the rate of 
hydrolytic activity (Table 3) for the two mutants, indicating that Cys149 does play some role 
in this process, potentially in substrate binding as suggested by the 8-oxo-GTP bound 
structure. The role of His246 is more complex; while the structural data suggests a role in 
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the second hydrolytic step (vide supra), the mutagenesis data instead implicate a more direct 
role in the late steps of the reaction and only a minor role in the steps involved in formate 
release. Thus, in our mechanistic proposal His246, while involved in H-bonding in the early 
steps of the reaction, does not participate directly in any chemical steps (Fig. 9A), but does 
participate in protonation of the ribose ring via an intervening water molecule in the second 
half of the reaction (Fig. 9B).
Notably, the proposal is also consistent with the observation that Cys149 can be nitrosylated 
(Fig. 10). S-nitroso groups on cysteine side chains can exist in several oxidation and 
protonation states, and computational quantum mechanical studies have shown that the 
dihedral angle and the S-N bond length is a function of its chemical state [24]. Accordingly, 
the staggered conformers seen in the 8-oxo-GTP-occupied sites and in the empty active sites 
(dihedral angle ∼103° and ∼122°, respectively) are consistent with the radical thionitroxide 
form C-S-NH-O•, while the almost planar CSNO conformer (dihedral angle ∼24°) seen in 
the TRIS-occupied active site represents the oxidized C-S-N=O form. The latter species, 
constituting a minority of states, may be an artifact of oxidation by O2 or X-ray exposure 
during data acquisition. Although detailed acid/base properties for these species have not 
been reported, they are observed to be involved in H-bonding interactions (e.g., Fig. 4) and 
presumed to readily undergo protonation/deprotonation reactions. It is not clear which atom 
of C-S-NH-O• serves as the site for deprotonating C2′, but we show this occurring on the 
oxygen (Fig. 10) since this position has been explicitly highlighted as a putative basic site 
[53].
Since its discovery GCYH-I has come to exemplify the chemical complexity possible for 
enzymatic catalysis, and it continues to astonish some five decades later. Remarkably, this 
complex reaction is now known to be catalyzed by two enzymes that, despite their common 
origin, share only two amino acids in common and bind GTP in markedly distinct ways. As 
a further surprise, an essential catalytic cysteine in a GCYH-IB family member undergoes 
nitrosylation to form a thionitroxide species, a post-translational modification heretofore 
associated only with metabolic regulation, here utilized directly in catalysis. While the 
formation of this modification of GCYH-IB in N. gonorrhoeae awaits confirmation, the 
observation that the enzyme undergoes site-specific nitrosylation in E. coli, and that 
nitrosylation enhances catalytic activity, offers an exciting new insight into the chemistry of 
GCYH-I, and potentially new roles for nitrosylation in biology.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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ATP adenosine 5′-triphosphate
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2′-dGTP 2′-deoxyguanosine triphosphate
7-deazaGTP 7-deazaguanosine 5′-triphosphate
DTT DL-dithiothreitol
BME β-mercaptoethanol
EDTA ethylenediaminetetraacetate
GCYH-I GTP cyclohydrolase I
GCYH-IA Type IA GTP cyclohydrolase
GCYH-IB Type IB GTP cyclohydrolase
GTP guanosine 5′-triphosphate
HEPES N-(2-hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid)
TRIS 2-Amino-2-hydroxymethyl-propane-1,3-diol
H2NTP 7,8-dihydroneopterin triphosphate
HPLC high-pressure liquid chromatography
MES 4-morpholineethanesulfonic acid
8-oxo-GTP 8-oxoguanosine 5′-triphosphate
PEG polyethylene glycol
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
T-fold tunnel fold
R.m.s.d root mean square deviation
GSH reduced glutathione
TBST TRIS-buffered saline and Tween 20
MWCO molecular weight cut-off
BSA bovine serum albumin
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Figure 1. 
The reaction catalyzed by GTP cyclohydrolase I, and the metabolic pathways in which it is 
found.
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Figure 2. 
Competitive inhibition of N. gonorrhoeae GCYH-IB with GTP analogs. Reactions were 
performed with varied GTP concentration (3-50 μM) and in the presence of various fixed 
concentrations of inhibitor. Activity was monitored by fluorescence with excitation at 365 
nm and emission at 446 nm. (A) 2′-dGTP: (•) 0, (□) 50, (◊) 100, and (○) 200 μM; (B) 7-
deaza-GTP: (•) 0, (□) 15, (◊) 30, and (○) 60 μM; and (C) 8-oxo-GTP: (•) 0, (□) 0.1, (◊) 
0.25, and (○) 0.5 μM. Data were fit to equation 1 using KaleidaGraph 4.0.
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Figure 3. 
Crystal structure of N. gonnorrhoae GCYH-IB in complex with 8-oxo-GTP. A) Side (left) 
and top (right) views of the enzyme homotetramer with subunits shown in different colors. 
Bound Zn2+ ions are shown as red spheres, and bound 8-oxo-GTP molecules in two of the 
four active sites in the homotetramer are shown in red stick representation.
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Figure 4. 
View of the active site of N. gonnorrhoae GCYH-IB with bound 8-oxo-GTP. A) Stereoview 
of the 2Fo-Fc electron density map (contour level 1.1 σ, resolution 2.77 Å), contoured 
around the bound Zinc ion, 8-oxo-GTP, and the nitrosylated Cys149, and superposed on the 
refined model. Zn2+ is shown as purple sphere, and water molecules as red spheres. Side 
chains interacting with 8-oxo-GTP are labeled and the subunits from which they originate 
are indicated in parentheses. B) Schematic of enzyme-inhibitor interactions. The ligand is 
shown in ball-and-stick representation. Dotted lines indicate hydrogen bonds or interactions 
with the metal ion. Residues are labeled as in panel A. For clarity, His246 and the water 
molecule W2 are not shown in panel B. The figure was made with the program LIG-PLOT 
[54].
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Figure 5. 
The TRIS occupied active site in the crystal structure of N. gonnorrhoae GCYH-IB in 
complex with TRIS. A) Stereoview of the 2Fo-Fc electron density map (contour level 1.3 σ, 
resolution 1.9 Å), contoured around the bound Zinc ion, TRIS, and the nitrosylated Cys149; 
and superposed on the refined model. Zn2+ is shown as purple sphere, and water molecules 
as red spheres. Side chains interacting with TRIS are labeled and the subunits from which 
they originate are indicated in parentheses. B) Schematic of enzyme-TRIS interactions. The 
ligand is shown in ball-and-stick representation. Dotted lines indicate hydrogen bonds or 
interactions within the metal coordination sphere. The figure was made with the program 
LIG-PLOT [54].
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Figure 6. 
View in the active site region of the superposition of the 8-oxo-GTP-bound structure (pink) 
and the TRIS-bound structure (grey). Zn2+ is shown as purple sphere, and water molecules 
as red spheres. For clarity, Ser61(A) is not shown. The ligand-coordinating side chains are 
shown and labeled as in figure 4. TRIS and 8-oxo-GTP atoms discussed in the text are 
labeled in black and pink, respectively. The water filled cavity serving as the putative 
formate binding site is marked with an asterisk.
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Figure 7. 
S-nitrosylation of N. gonnorrhoae GCYH-IB. A) iodoTMT-switch assay of freshly purified 
wild-type GCYH-IB, of the enzyme after treatment with 0.5 mM GSH, and of the 
Cys149Ala mutant. Top: Western blot of TMT-labeled proteins visualized using an anti-
TMT antibody. Bottom: Coomassie Brilliant Blue staining of the same gel showing equal 
loading in all lanes. B) Relative H2NTP producing activities of the enzyme samples in panel 
A as measured using the fluorescence assay. The error bars indicate the standard error of 
triplicate measurements.
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Figure 8. 
Comparison between GCYH-IB (left) and GCYH-IA (right) ternary complexes with zinc 
and 8-oxo-GTP showing interactions in the active site. Cα chains and active site residues are 
shown as ribbons and sticks, respectively. Subunits A, B and B′ are colored orange, cyan 
and magenta, respectively. Hydrogen bonds and Zinc ion interactions are shown as dashed 
yellow lines. A) The Zinc-binding site and common distorted tetrahedral coordination 
geometry. Two subunits contribute ligands to the metal site in the -IB enzyme, whereas in 
the -IA enzyme, all ligands originate from one subunit. B) The purine and ribose binding 
pocket showing similar interactions and mode of binding for the purine ring and rotation of 
the ribosyl group (the triphosphate tail was removed from this view for clarity). C) 
Hydrogen-bond interactions for the triphosphate moiety. One subunit contributes residues to 
stabilization of the triphosphate in the –IB enzyme, whereas in the –IA enzyme, all three 
interface subunits participate.
Paranagama et al. Page 30
A
uthor M
anuscript
Figure 9. 
Proposed mechanism for the GCYH-IB catalyzed reaction. A) The early hydrolytic steps in 
the reaction leading to the formation of formic acid and the intermediate 2,5-diamino-(6β)-
ribosylamino-4(3H)-pyrimidinone 5′-triphosphate (DRPT). B) The later steps in the reaction 
involving the conversion of DRPT to H2NTP.
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Figure 10. 
Proposed mechanism for the participation of the thionitroxide of Cys149 in catalysis.
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Table 1
Competitive inhibition constants for N. gonorrhoeae GCYH-IB with substrate analogs.
Inhibitor Ki (μM)a Ki/Km
2′-deoxyGTP 164.2 ± 3.1 24.3
7-deaza-GTP 45.7 ± 1.5 6.8
8-oxo-GTP 0.149 ± 0.0049 0.022
a
Values are presented with respect to their standard errors.
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Table 2
X-ray data collection parameters and structure refinement statistics.
Parameter Value Value
Data collection
Structure TRIS complex 8-oxo-GTP complex
Beamline ALS-5.0.1 ALS-5.0.1
Space group C 2 2 21 C 2 2 21
Unit cell (Å) 92.71, 100.56, 114.02 91.88, 100.56, 115.04
Resolution (Å) 68.16-1.9 (1.95-1.9) 67.83-2.77 (2.90-2.77)
Wavelength (Å) 0.9774 0.9774
Unique Reflections 41,799 (2,2068) 13,898 (1,297)
Completeness (%)a 99.2 (91.6) 99.7 (96.8)
Redundancy 4.4 (2.7) 8.4 (6.0)
Rsym b 0.053 (0.45) 0.076 (0.67)
 Average I/σ(I) 36.4 (2.1) 16.4 (1.2)
Refinement statistics
Resolution range (Å) 68.1-1.9 67.8-2.8
Rcrsyt c 0.172 0.19
Rfreed 0.208 0.25
R.m.s. deviation from ideality
Bond length (Å) 0.019 0.010
 Bond angle (°) 1.89 1.49
Average B factor (Å2) 42.4 61.6
Ramachandran plot:
Preferred (%) 94.4 90.8
Allowed (%) 5.6 6.8
Outlier (%) 0.0 2.4
a
Values in parentheses are for the highest-resolution shell.
b
Rsym = Σ|Iobs − <I>|/Σ Iobs.
c
Crystallographic R-factor = Σ||Fobs| − |Fcalc||/Σ|Fobs|.
d
Rfree is monitored with 5% of the reflections excluded from the refinement.
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Table 3
Relative catalytic activities (%) of GCYH-IB mutants.
Protein Radiochemicala UV-visa
Wild-type 100 100
E152A 24.7 21.4
E243A 0.36 0.37
C149A 11.0 NAb
C149S 17 2.7
H246A 2.0 0.74
H246D 72 3.0
H246Q 67 2.4
H246N 24 NA
H246K 5.0 NA
a
Activity reflects the relative initial velocities determined via the radiochemical and UV-vis time course assays, which quantify the formation of 
[14C]-HCO2H and H2NTP, respectively. Standard errors for the initial velocity measurements calculated from the radiochemical and UV-vis data 
varied from 2-8% and 2.5-10%, respectively.
b
NA indicates that no activity was detected. Detection limits were 0.25% of wild-type activity.
